Search | ECR Journal

European Cardiology Review

Journal Impact Factor: 3.6

Back to Main Menu

View all platforms

Content for healthcare professionals only

Search results

Ticagrelor Fails Noninferiority to Prasugrel in TUXEDO-2

News

Added: 3 months ago Source: Radcliffe CVRM

Written by Mirjam Boros, Radcliffe CardiologyThe optimal dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) in high-risk patients with diabetes and multivessel disease remains a key clinical question. The TUXEDO-2 trial aimed to address this by directly comparing the efficacy and safety of ticagrelor versus prasugrel in this specific patient population… View more

Anticoagulation

Cardiovascular Kidney Metabolic

AHA 25: TUXEDO-2: Ticagrelor vs Prasugrel in Diabetic PCI

AHA 25 Late-breaking Discussion: Comparison from the TUXEDO-2 Trial

Video

Author(s): Sripal Bangalore , Harriette Van Spall Added: 7 months ago

AHA Scientific Sessions 2025 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) was joined by the TUXEDO-2 Principal Investigator, Dr Sripal Bangalore to present the findings of this late-breaking randomized trial comparing ticagrelor versus prasugrel in patients with diabetes mellitus and multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI)… View more

Anticoagulation

Intervention

EuroPCR 24: The CAGEFREE II Trial

Video

Author(s): Ling Tao Added: 2 years ago

EuroPCR 2024 — Investigator, Dr Ling Tao joins us to discuss the findings from the CAGEFREE II trial.Compared to drug-eluting stents, drug-coated balloons are associated with faster vessel healing and reduced thrombotic burden, therefore patients treated with DCBs require a less intensive antiplatelet therapy. CAGEFREE II investigated the effectiveness and safety of a tailored one-month DAPT… View more

Intervention

Oral P2Y12 Inhibitors and Drug Interactions

Review Article

Author(s): Elisabetta Bigagli , Jacopo Angelini , Alessandro Mugelli , et al Added: 1 year ago

Anticoagulation

Prevention & Chronic Conditions

ACC 25: The Phase 3 REVERSE-IT Trial

Video

Author(s): Deepak L Bhatt Added: 1 year ago

ACC 2025 - Phase three results of the use of bentracimab in patients who need urgent ticagrelor reversal show significantly restored platelet function as measured by percent inhibition of P2Y12 Reaction Unit (PRU).Dr Deepak L Bhatt (Mount Sinai Fuster Heart Hospital, New York, US) joins us onsite at ACC 2025 to discuss phase three results from the multi-center, open-label, single-arm REVERSE-IT… View more

Anticoagulation